Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Adam on +44 1494 818 010 or adam@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
adam@zenopa.com
+44 1494 818 010

Testimonials
Zenopa’s help and support throughout my recent recruitment process was invaluable. It was a big decision for me to change careers and it would have been a lot more stressful and daunting without the...
Phil, 2014

Shire receives award for rare disease research

5 March 2012 00:00 in Pharmaceutical Company Product News


Shire has been presented with a prestigious accolade from the European Organisation for Rare Diseases (Eurordis) for its pioneering work in developing new therapies for uncommon illnesses.

The pharmaceutical company has been granted the Eurordis Company Award for its commitment to working with patient groups in order to create new drugs, as well as its efforts to make the products as accessible as possible across the EU.

It coincided with Rare Disease Day, a global event designed to raise awareness of rare conditions and the healthcare challenges faced by those affected, such as the difficulty of obtaining the relevant diagnoses, support, therapies and information.

Sylvie Gregoire, president of Shire Human Genetic Therapies, said the company looks forward to collaborating with Eurordis further in the future.

She added: "This award embodies the spirit of our organisation - every employee at Shire is dedicated to developing and bringing forward new products, services and support offerings which can make a positive impact on patients' lives."

Last month, the European Medicines Agency granted Shire approval to use its new manufacturing site in Lexington, Massachusetts to expand the global supply of Vpriv, its treatment for type 1 Gaucher disease.ADNFCR-8000103-ID-801309259-ADNFCR

Other news stories from 05/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2015 Zenopa Ltd